Insider Selling: Teladoc, Inc. (TDOC) VP Sells 10,000 Shares of Stock
Teladoc, Inc. (NYSE:TDOC) VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $34.04, for a total value of $340,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Mark Hirschhorn also recently made the following trade(s):
- On Friday, September 22nd, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The stock was sold at an average price of $31.93, for a total transaction of $798,250.00.
Shares of Teladoc, Inc. (NYSE:TDOC) traded up 0.29% during midday trading on Wednesday, reaching $34.80. 488,739 shares of the company’s stock traded hands. Teladoc, Inc. has a one year low of $14.00 and a one year high of $37.55. The company’s market capitalization is $1.97 billion. The company has a 50-day moving average of $33.17 and a 200-day moving average of $33.17.
Teladoc (NYSE:TDOC) last announced its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). The company had revenue of $44.60 million during the quarter, compared to analysts’ expectations of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. Teladoc’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.38) EPS. Equities research analysts anticipate that Teladoc, Inc. will post ($1.44) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Insider Selling: Teladoc, Inc. (TDOC) VP Sells 10,000 Shares of Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/insider-selling-teladoc-inc-tdoc-vp-sells-10000-shares-of-stock.html.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. ETF Managers Group LLC purchased a new position in Teladoc during the second quarter worth $104,000. Great West Life Assurance Co. Can bought a new position in Teladoc during the first quarter valued at $105,000. US Bancorp DE increased its position in Teladoc by 10.3% during the first quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after acquiring an additional 433 shares during the last quarter. Bank of Montreal Can increased its position in Teladoc by 214.2% during the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after acquiring an additional 2,397 shares during the last quarter. Finally, Pacad Investment Ltd. purchased a new stake in shares of Teladoc in the second quarter valued at $135,000.
A number of equities research analysts have recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and issued a $42.00 price objective (up from $34.00) on shares of Teladoc in a report on Tuesday, June 20th. Chardan Capital increased their target price on shares of Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, June 20th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 target price on shares of Teladoc in a report on Friday, July 28th. KeyCorp reaffirmed a “buy” rating and set a $37.00 target price on shares of Teladoc in a report on Sunday, September 17th. Finally, Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “buy” rating and set a $38.00 target price on the stock in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Teladoc currently has an average rating of “Buy” and an average target price of $38.00.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.